Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSPREY: Brolucizumab vs Aflibercept in Wet AMD
NCT01796964Phase 2Completed
- Sponsor
- Alcon Inc.
- Start
- Mar 2013
- Primary completion
- Oct 2013
- Modality
- scFv Fragments, Monoclonal Antibodies
01
Overview
A Phase 2 trial of brolucizumab in exudative age-related macular degeneration, sponsored by Alcon Inc.. Started Mar 2013; status: completed.
02
Drugs
brolucizumab
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT01796964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01796964.